Get the Stockscreener App
0.775
6.85%
-0.057
After Hours:
.78
0.005
+0.65%
Tiziana Life Sciences Ltd stock is traded at $0.775, with a volume of 568.05K.
It is down -6.85% in the last 24 hours and down -22.50% over the past month.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
See More
Previous Close:
$0.832
Open:
$0.8
24h Volume:
568.05K
Relative Volume:
1.92
Market Cap:
$80.46M
Revenue:
-
Net Income/Loss:
$-13.73M
P/E Ratio:
-5.0987
EPS:
-0.152
Net Cash Flow:
$-3.92M
1W Performance:
-17.65%
1M Performance:
-22.50%
6M Performance:
-1.49%
1Y Performance:
+30.79%
1-Day Range:
$0.738
$0.831
1-Week Range:
$0.73
$1.0722
52-Week Range:
$0.41
$1.74
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Name
Tiziana Life Sciences Ltd
Sector
Industry
Phone
-
Address
-
Compare TLSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
0.775 | 80.46M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Dec-17-18 | Initiated | Laidlaw | Buy |
Tiziana Life Sciences Ltd Stock (TLSA) Latest News
Tiziana Life Sciences doses first Alzheimer’s patient with intranasal foralumab - Proactive Investors Australia
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab - The Manila Times
Tiziana Life Sciences Launches Novel Alzheimer's Treatment Trial with Groundbreaking Intranasal Therapy - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Drop in Short Interest - MarketBeat
3 US Penny Stocks With Market Caps Under $200M To Consider - Simply Wall St
17% Gain Today – This Stock Isn’t Done Yet - RagingBull
Tiziana Life Sciences expands Phase 2 trial for non-active SPMS - Yahoo Finance
Tiziana broadens Phase 2 trial for MS therapy By Investing.com - Investing.com Canada
Tiziana Life Sciences expands Phase 2 MS trial to additional top US medical institutions - Proactive Investors Australia
U.S. Dollar Index (DXY) QuotePress Release - The Globe and Mail
PHLX Canadian Dollar (XDC) QuotePress Release - The Globe and Mail
TSX Industrials EW Index (TXIE) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Tiziana broadens Phase 2 trial for MS therapy - Investing.com India
S&P 500 Communication Services [Sector] (SRTS) QuotePress Release - The Globe and Mail
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers - The Manila Times
Tiziana Life Sciences Expands Breakthrough MS Drug Trial to Elite U.S. Medical Centers - StockTitan
Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 3.7%Here's What Happened - MarketBeat
Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 3.7% – Here’s What Happened - Defense World
Tiziana Life Sciences Secures ALS Trial Funding - Yahoo Finance
Tiziana Life Sciences secures grant for ALS trial - Proactive Investors USA
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association - The Manila Times
Tiziana Life Sciences Secures ALS Association Grant for Breakthrough Foralumab Trial | TLSA Stock News - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Growth in Short Interest - MarketBeat
Tiziana Life Sciences CEO discusses foralumab potential to enhance OzempicICYMI - Proactive Investors USA
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference - Proactive Investors UK
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data - The Manila Times
Tiziana Life Sciences secures funding to advance development of MS and Alzheimer’s therapy - Proactive Investors USA
Tiziana Life Sciences Plans Share Sale with Jefferies - MSN
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million - The Manila Times
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study - GlobeNewswire
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million - GlobeNewswire Inc.
Tiziana reports progress in obesity inflammation study By Investing.com - Investing.com South Africa
Tiziana Life Sciences : announces plans for clinical development of foralumab, the company’s fully human CD3 antibody - Marketscreener.com
Tiziana Life Sciences' Semaglutide combo shows potential in obesity-related liver inflammation - Proactive Investors USA
TLSATiziana Life Sciences Ltd. Common Shares Latest Stock News & Market Updates - StockTitan
Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesity - Proactive Investors UK
Tiziana reports progress in obesity inflammation study - Investing.com
Proactive news headlines: Helix, Hemogenyx, DEC, Ananda, Thor Energy, Bradda Head and more - Proactive Investors UK
Discover October 2024's Promising US Penny Stocks - Simply Wall St
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Tiziana Life Sciences Advances with Promising Drug Trials - Yahoo Finance
Tiziana Life Sciences reports interim results, updates on programs - Investing.com India
Tiziana Life Sciences Ltd Stock (TLSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):